# An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

> **NCT00076635** · PHASE3 · TERMINATED · sponsor: **InterMune** · enrollment: 91 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Pulmonary Fibrosis
- Lung Disease

## Interventions

- **DRUG:** Interferon gamma-1b

## Key facts

- **NCT ID:** NCT00076635
- **Lead sponsor:** InterMune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** program discontinued based on GIPF-007 results
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076635, "An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00076635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*